Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M

PUMA BIOTECHNOLOGY, INC.

2025-FY EPS reported $0.61 revenue$228,371,000

Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.
GAAP net income Q4 2025 $13.4M ($0.27 basic) vs $19.3M ($0.39) YoY; non-GAAP adjusted net income $15.1M ($0.30).
Full year 2025 total revenue $228.4M; GAAP net income $31.1M ($0.62) vs $30.3M ($0.62) YoY.
Cash, equivalents & marketable securities $97.5M; total debt reduced to $22.5M from $67.0M at end of 2024.
FY2026 guidance: net product revenue $194-198M; total revenue $214-221M; net income $10-13M, excluding valuation allowance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.